(Q36635872)

15 August 2017

1 reference

title

Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications (English)

1 reference

Helicobacter pylori infectious disease

15 August 2017

0 references

1 reference

3

Ernst J Kuipers

1 reference

15 August 2017

Monique M Gerrits

1

1 reference

PubMed ID

17067919

15 August 2017

Arnoud H M van Vliet

series ordinal

2

1 reference

PubMed ID

17067919

15 August 2017

Johannes G Kusters

series ordinal

4

1 reference

15 August 2017

1 November 2006

1 reference

Lancet Infectious Diseases

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

11

1 reference

15 August 2017

699-709

1 reference

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Pathogenesis of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Helicobacter pyloriInfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Helicobacter in the developing world

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Review article: after gastritis--an imaginary journey into a Helicobacter-free world

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Helicobacter pylori. Pathology and diagnostic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Eradication of Helicobacter pylori in clinical situations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

The CLO test in the UK: inappropriate reading and missed results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Is routine histological evaluation an accurate test for Helicobacter pylori infection?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Any role left for invasive tests? Histology in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Antibiotic resistance in Helicobacter pylori: implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Review article: the treatment of refractory Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Helicobacter pylori "rescue" therapy after failure of two eradication treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Treatment of Helicobacter pylori infection: a review of the world literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin-susceptible and-resistant Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

The actions of bismuth in the treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Bismuth therapy in gastrointestinal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Helicobacter pylori therapy: first-line options and rescue regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Treatment and management of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Regular review: treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Treatment of Helicobacter pylori Eradication Failures.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Resistance of Helicobacter pylori to antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. The Gastrointestinal Physiology Working Group of Universidad Peruana Cayet

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Amoxycillin tolerance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Resistance of helicobacter pylori to metronidazole, tetracycline and amoxycillin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Clinical relevance of resistant strains of Helicobacter pylori: a review of current data

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Antibiotic resistance problems with Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

H pylori antibiotic resistance: prevalence, importance, and advances in testing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Review article: nitroimidazole resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Stable amoxicillin resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Molecular patchwork: Chromosomal recombination between two Helicobacter pylori strains during natural colonization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Metronidazole resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

The complete genome sequence of the gastric pathogen Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Macrolide resistance conferred by base substitutions in 23S rRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

New mutation points in 23S rRNA gene associated with Helicobacter pylori resistance to clarithromycin in northeast China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Identification of a novel mutation affecting domain V of the 23S rRNA gene in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Stable amoxicillin resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

DNA gyrase: structure and function.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Antimicrobial activity of rifabutin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Subpopulations of Helicobacter pylori are responsible for discrepancies in the outcome of nitroimidazole susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Detection of clarithromycin-resistant Helicobacter pylori in stool samples.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Modulation of host antimicrobial peptide (beta-defensins 1 and 2) expression during gastritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Synthesis of reversed magainin 2 analogs enhanced antibacterial activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Antimicrobial properties of porphyrins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Essential Oils as Components of a Diet-Based Approach to Management of Helicobacter Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Antimicrobial activity of essential oils against Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970627-2

7 January 2021

10.1016/S1473-3099(06)70627-2

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17067919